AMY-101 acetate

AMY-101acetate(Cp40acetate)是补体C3的肽类抑制剂(KD=0.5nM)，可抑制非人类灵长类动物自然发生的牙周炎。AMY-101acetate(Cp40acetate)在COVID-19重症肺炎合并全身超炎症模型中具有良好的抗炎活性。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥3987.00

3190.00

- +
5mg

￥9825.00

7860.00

- +
10mg

￥16350.00

13080.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajcx30154
CAS: N/A
别名: Cp40 acetate
分子式: C85H121N23O20S2
分子量: 1849.16
纯度: >98%
溶解度: DMSO: 100 mg/mL (54.08 mM); Water: < 0.1 mg/mL (insoluble)
储存: -20°C, protect from light
库存: 现货

Background

AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation[1][2].

AMY-101 can improve the periodontal condition of NHPs with natural chronic periodontitis[1].AMY-101 can induce a long-lasting anti-inflammatory effect[1].AMY-101 (4 mg/kg bodyweight, subcutaneous injection. once per 24 hr for a total of 28 days) causes a significant and long-lasting reduction in PPD, an index that measures tissue destruction[1]. Animal Model: Fifteen adult male cynomolgus monkeys (Macaca fascicularis) (7-15 years old; 5.0-7.6 kg body weight)[1].

[1]. Kajikawa T, et al. Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. Mol Ther Methods Clin Dev. 2017 Aug 18;6:207-215. [2]. Mastaglio S, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Apr 29:108450.